Mark S. Shearman. Ongoing Progress in the Phase 1/2 BRILLIANCE Clinical Trial for Treatment of CEP-290 Retinal Degeneration: In vivo CRISPR gene editing therapies for ocular disease. Presented at TIDES USA Oligonucleotide & Peptide Therapeutics. May 9 – 13, 2022.

Apr

22

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Feb

28

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

Feb

21

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events